Discontinued — last reported Q2 '21
Merck & Co. Unrecognized Tax Benefits - Impacting Effective Tax Rate increased by 13.6% to $2.50B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.6%, from $2.20B to $2.50B. Over 5 years (FY 2020 to FY 2025), Unrecognized Tax Benefits - Impacting Effective Tax Rate shows an upward trend with a 10.8% CAGR.
An increase suggests higher tax uncertainty, while a decrease may indicate the resolution of tax audits or the expiration of statutes of limitations.
This represents the portion of tax positions taken by the company that have not been recognized in the financial stateme...
Highly dependent on the company's global tax footprint and audit environment; peers with similar international operations show comparable levels of tax uncertainty.
unrecognized_tax_benefits_impacting_etr| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.50B | $1.80B | $2.30B | $2.20B | $2.50B |
| QoQ Change | — | +20.0% | +27.8% | -4.3% | +13.6% |
| YoY Change | — | +20.0% | +27.8% | -4.3% | +13.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.